Abstract: A rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin, sugar alcohol (e.g., mannitol), and a flavorant and (b) an active therapeutic ingredient (ATI). Preferred rapidly infusing compositions are those formulated with a PDE5 inhibitor as the ATI. A method of administering an ATI such as a PDE5 inhibitor to a subject is also disclosed. The subject is administered the rapidly infusing composition via the oral mucosa to treat a condition responsive to inhibition of PDE5, for example, erectile dysfunction.

Abstract: A rapidly infusing composition that includes a pharmaceutically acceptable binder and/or excipient system containing mammalian gelatin and a sugar alcohol, and at least one supplement selected from the group consisting of a vitamin D compound, vitamin A, vitamin E, vitamin K, vitamin B, vitamin C, and caffeine. Also disclosed is a method of providing nutrient supplementation/modulation and/or a stimulant effect to a subject, whereby the subject in need thereof is administered, via the oral mucosa, the rapidly infusing composition.

Abstract: A rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) active therapeutic ingredient (ATI). Preferred rapidly infusing compositions are those formulated with tetrahydrocannabinol or a derivative/analog thereof as the ATI. A process for manufacturing the rapidly infusing composition and a method of administering an ATI such as tetrahydrocannabinol or a derivative/analog thereof, to a subject is also disclosed. The subject is administered the rapidly infusing composition via the oral mucosa to activate cannabinoid receptors in the subject, for example to treat conditions such as, inter alia, anorexia, cachexia, nausea, emesis, pain, spasticity, fibromyalgia, overactive bladder, sleep apnea, and/or glaucoma.

Abstract: A rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) active therapeutic ingredient (ATI). Preferred rapidly infusing compositions are those formulated with nicotine or a derivative/analog thereof as the ATI. A method of administering an ATI such as nicotine or a derivative/analog thereof, to a subject is also disclosed. The subject is administered the rapidly infusing composition via the oral mucosa, for example, to reduce the subject's usage of more harmful nicotine delivery methods and/or nicotine withdrawal symptoms.

Abstract: A stick composition made of cannabidiol and/or tetrahydrocannabinol and waxes or solid-oils. The stick composition provides an effective dosage level of cannabidiol and/or tetrahydrocannabinol without unpleasant odors. The stick composition is applied topically for treating or reducing pain. In some instances, the cannabidiol and/or tetrahydrocannabinol may be the only active therapeutic agent present. The stick composition may also include one or more additives such as a vitamin, an essential oil, a flavorant, or a perfume.

Abstract: A composition and method of treatment in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount of an active therapeutic ingredient (ATI). Preferably, a composition and method of treating pain in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount cannabidiol (CBD).

Abstract: A composition and method of treatment in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount of an active therapeutic ingredient (ATI). Preferably, a composition and method of treating pain in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount cannabidiol (CBD).